Cyclacel pharmaceuticals confirms it has filed an appeal to nasdaq staff delisting letter

Berkeley heights, n.j., sept. 03, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the company timely requested a hearing before the nasdaq hearings panel (the “panel”) and a hearing has been scheduled for october, 15, 2024.
CYCC Ratings Summary
CYCC Quant Ranking